ImmunoPrecise Antibodies Ltd.
IPA
$3.20
$0.5721.67%
NASDAQ
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 89.96% | -709.93% | 35.98% | 77.50% | -554.25% |
| Total Depreciation and Amortization | -33.75% | -5.22% | 1.66% | 1.61% | 2.16% |
| Total Amortization of Deferred Charges | -100.00% | -3.79% | 6.45% | -92.84% | -- |
| Total Other Non-Cash Items | -97.15% | 23,091.74% | 76.32% | -102.18% | 2,688.78% |
| Change in Net Operating Assets | -156.70% | 167.52% | -193.64% | 727.77% | -119.25% |
| Cash from Operations | 5.25% | 48.47% | -23.32% | -14.33% | -52.42% |
| Capital Expenditure | -220.56% | -65.55% | 75.22% | 76.87% | -779.62% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | 114.75% |
| Cash from Investing | -220.56% | -65.55% | 75.22% | 76.54% | -2,040.28% |
| Total Debt Issued | -100.00% | -87.47% | -43.82% | -- | -- |
| Total Debt Repaid | -27.57% | 16.22% | -3.30% | -30.46% | 6.21% |
| Issuance of Common Stock | -99.84% | 953.54% | 106.92% | -65.54% | 52.41% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -103.96% | 389.74% | -23.04% | 137.90% | 82.29% |
| Foreign Exchange rate Adjustments | -294.06% | 205.07% | 8.89% | 87.01% | -313.70% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -123.59% | 2,478.75% | -183.54% | 116.43% | -1,576.06% |